Loading...

MLYS MINERALYS THERAPEUTICS INC Other Situations 8-K Filing

MNRL

MLYS

MINERALYS THERAPEUTICS INC

(MLYS)

2026 8-K

Financial Results Announcement

FDA NDA Acceptance

Corporate Update

Financial Update

Stock Offering Details

Termination Notice

Product Expansion

Financial Statements

Financial Results

Trial Enrollment Complete

Financial Results

Trial Enrollment Complete

Trial Enrollment Complete

Financial Results

Appointment and Resignation

Clinical Trials Update

Earnings Report

Departure of Directors

Equity Offering

Private Placement

Appointment of Chief Busine...

Announcement of Launch-HTN ...

Data Presentation

Financial Results Announcement

Resignation and Appointments

Financial Results Announcement

Expansion of Phase 2 Trial

Earnings Report

Departure of Directors or C...

Financial Results Announcement

Amended Certificate and Bylaws

External Links:

On January 6, 2026, Mineralys Therapeutics, Inc. announced its participation in a corporate access event on January 12-14, 2026, and disclosed the filing of a new drug application for lorundrostat with the FDA in late 2025, along with expected topline results from its Phase 2 trial in the first quarter of 2026.

AI Assistant

MINERALYS THERAPEUTICS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.